Journal info
|
||
Select Journal
Journals
Bratislava Medical Journal Endocrine Regulations General Physiology and Biophysics Neoplasma 2024 Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
Neoplasma Vol.52, p.43-45, 2005 |
||
Title: Comparison of the serum erythropoietin levels in chemotherapy- naive and cisplatin-treated cancer patients | ||
Author: M., ARSLAN ; T., EVRENSEL ; E., KURT ; M., DEMIRAY ; I., ERCAN ; O., KANAT ; A., OZKAN ; O., MANAVOGLU ; | ||
Abstract: There are conflicting data about the effects of cisplatin on
erythropoietin (EPO) response to anemia. Aim of our study was to
investigate whether endogenous EPO response to anemia in cisplatin
treated patients was insufficient in comparison to the anemic
chemotherapy-naive cancer patients and non cancer patients with
iron deficiency anemia. Patients who had hemoglobin (Hb) levels of
less than 110 g/l were included in the study. Fifteen chemotherapy-
naive cancer patients were enrolled in Group A. Group B consisted
of 15 patients who had been treated with three cycles of cisplatin
chemotherapy and then became anemic and in Group C were included
15 patients who had iron deficiency anemia, without any
malignancy. The mean Hb values were not different between all
groups (102.8Ż39.8 g/l, 103.1Ż2.5 g/l and 99.3Ż3.6 g/l in Group A,
Group B and Group C, respectively). However, EPO levels were found
to be significantly lower in Group A and Group B than Group C
(29.63Ż9.09 mU/ml, 20.87Ż2.43 mU/ml and 85.38Ż25.72 mU/ml,
respectively; p=0.017 Group A vs. Group C, p=0.005 Group B vs.
Group C). No significant difference was found between Group A and
B (p=0.917).
Opposite the iron deficiency anemia, cancer anemia is associated
with an inadequate EPO response to anemia and administration of
cisplatin does not lead to it further deterioration.
|
||
Keywords: anemia, erythropoietin, cisplatin, cancer | ||
Year: 2005, Volume: 52, Issue: | Page From: 43, Page To: 45 | |
|
download file |
|